Filing Flows

Filing Flows › Companies › Insight Molecular Diagnostics › Cash flow

Insight Molecular Diagnostics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$10.0M in Q2 2026 · −$31.0M over twelve months

Operating cash flow−$9.3M
Capital spending−$779K
Free cash flow−$10.0M
Cash conversion cycle-1541 days

Analysis

In Q2 2026, Insight Molecular Diagnostics generated −$9.3M of operating cash flow and spent $779K on capital projects, leaving free cash flow of −$10.0M. That is $3.5M less than in Q2 2025 (−$6.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$27.1M; the largest uses were operating cash flow ($27.1M), capital spending ($3.9M), other financing ($1.4M); besides operations, cash came from shares issued ($26.0M); the cash balance fell by $7.3M.

Operating cash flow was −$9.3M against net income of −$11.3M. The largest differences: payables −$1.1M, depreciation & amortization +$665K, stock-based pay +$661K.

Its cash conversion cycle was -1541 days (receivables 66 + inventory 327 − payables 1934): suppliers fund its working capital.

Free cash flow

Insight Molecular Diagnostics: free cash flow by quarterInsight Molecular Diagnostics: free cash flow by quarter−$5.6MQ3 2024−$5.6MQ4 2024−$6.1MQ1 2025−$6.5MQ2 2025−$5.7MQ3 2025−$7.0MQ4 2025−$8.3MQ1 2026−$10.0MQ2 2026
Operating cash flow less capital spending.
Insight Molecular Diagnostics: operating cash flow against capital spendingInsight Molecular Diagnostics: operating cash flow against capital spendingOperating cash flowCapital spending−$5.5M$87KQ3 2024−$5.4M$214KQ4 2024−$5.8M$307KQ1 2025−$6.2M$349KQ2 2025−$4.6M$1.1MQ3 2025−$5.5M$1.5MQ4 2025−$7.6M$613KQ1 2026−$9.3M$779KQ2 2026
Latest (Q2 2026): Operating cash flow −$9.3M, Capital spending $779K.

Capital allocation, year by year

Insight Molecular Diagnostics: where the cash came from (up) and went (down), by fiscal yearInsight Molecular Diagnostics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$35.9MFY2021: Net borrowing −$1.5MFY2021: Shares issued $67.8MFY2021: Capital spending −$2.2MFY2021: Acquisitions −$607K$67.8MFY2021FY2022: Operating cash flow −$45.6MFY2022: Net borrowing −$1.4MFY2022: Shares issued $32.8MFY2022: Capital spending −$4.3M$32.8MFY2022FY2023: Operating cash flow −$23.3MFY2023: Net borrowing −$117KFY2023: Shares issued $13.8MFY2023: Capital spending −$281K$13.8MFY2023FY2024: Operating cash flow −$20.7MFY2024: Net borrowing −$201KFY2024: Shares issued $26.0MFY2024: Capital spending −$516K$26.0MFY2024FY2025: Operating cash flow −$22.2MFY2025: Net borrowing −$510KFY2025: Shares issued $29.1MFY2025: Capital spending −$3.2M$29.1MFY2025
Over these 5 years operating cash flow totalled −$148M; the largest uses were operating cash flow ($148M) and capital spending ($10.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$17.8M
Debtnone
Net cash$17.8M
Cash runway7 months

Insight Molecular Diagnostics is burning cash: its operations consume cash, a free cash flow of −$31.0M a year at the current rate against $17.8M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Insight Molecular Diagnostics: sources (+) and uses (−) of cash, Q2 2026Insight Molecular Diagnostics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$10.6MOperating cash flow−$9.3MCapital spending−$779KOther financing−$412KNet borrowing (+) / repaid (−)−$152KExchange rates−$16K
Insight Molecular Diagnostics: sources (+) and uses (−) of cash, TTM to Q2 2026Insight Molecular Diagnostics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$27.1MShares issued$26.0MCash drawn (+) / kept (−)$7.3MCapital spending−$3.9MOther financing−$1.4MNet borrowing (+) / repaid (−)−$593KTaxes on employees’ shares−$309KExchange rates−$22K

From profit to cash

Insight Molecular Diagnostics: net income to operating cash flow, Q2 2026Insight Molecular Diagnostics: net income to operating cash flow, Q2 2026Net income−$11.3MDepreciation & amortization$665KStock-based pay$661KReceivables−$35KInventory$175KPayables−$1.1MPrepaid and other assets−$589KOperating cash flow−$9.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026663271934-1541
Q1 20261807219211009-7010
Q4 20255666258-136
Q3 2025136443887-308
Q2 2025356291899-252
Q1 202510848217-60
Q4 20245634133-43

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$9.3M−$779K−$152K—$10.6M−$10.0M
Q1 2026−$7.6M−$613K−$143K$26.0M−$16.4M−$8.3M
Q4 2025−$5.5M−$1.5M−$178K—$7.3M−$7.0M
Q3 2025−$4.6M−$1.1M−$120K—$5.8M−$5.7M
Q2 2025−$6.2M−$349K−$114K—$6.7M−$6.5M
Q1 2025−$5.8M−$307K−$98K$29.1M−$22.4M−$6.1M
Q4 2024−$5.4M−$214K−$82K$10.2M−$5.3M−$5.6M
Q3 2024−$5.5M−$87K−$86K—$5.9M−$5.6M

Insight Molecular Diagnostics: income statement and cash flow

Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year). The chart follows the revenue to costs, profit and cash.

Insight Molecular Diagnostics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.